Becton, Dickinson and Company (BDX)

BDX's stock price has declined by 23.83% between July 17, 2024, and July 16, 2025, with a range of $163.33 to $207.32 over the past six months. Several analyst downgrades have occurred, including Citigroup, Piper Sandler, and William Blair downgrading BDX to Neutral or Market Perform. Waters Corporation announced a deal to acquire BD's Biosciences & Diagnostic Solutions division for $17.5 billion, which aims to boost Waters' scale but carries execution and integration risks.

While specific details on demand seasonality are not explicitly provided, the nature of BD's business suggests relatively stable demand due to consistent healthcare needs. Regulatory approvals and product availability can significantly impact demand, as seen with the estimated $1 billion in pent-up demand for BD's Alaris infusion system. The broader medical technology sector is driven by factors such as an aging global population and technological advancements, contributing to consistent demand. However, demand for certain raw materials can be influenced by broader economic factors.

Becton, Dickinson and Company (BDX), also known as BD, is a global medical technology company established in 1897. It develops, manufactures, and sells a wide array of medical supplies, devices, laboratory equipment, and diagnostic products, serving healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public worldwide. The company operates within the Healthcare sector and the Medical Equipment & Supplies industry. BD's business is divided into three segments: BD Medical, which focuses on medication delivery and surgical procedures; BD Life Sciences, which provides products for diagnostic specimen collection and infectious disease detection; and BD Interventional, which offers products for surgical repair and critical care.

BD has a strong global presence, operating in over 190 countries with more than 75,000 employees. International revenues have historically accounted for over 50% of total revenues. The company markets its products internationally, with primary markets including Europe, Japan, Asia Pacific, Canada, and Latin America. BD maintains manufacturing facilities in numerous countries, including Brazil, China, France, Germany, India, Ireland, Japan, Korea, Mexico, Pakistan, Singapore, Spain, Sweden, and the United Kingdom.

BD's brand reputation has been impacted by legal and regulatory issues, including settled charges with the SEC for misleading investors about risks associated with its Alaris infusion pump and overstating its income, leading to a $175 million civil penalty. Despite these challenges, BD was recognized for its transparency, ranking in the top 10 and receiving the "Best Code of Conduct" award among S&P 250 companies in the U.S. Transparency Awards by Labrador.

Becton, Dickinson & Co. is a publicly traded company with a diverse ownership base. Institutional investors hold approximately 87% of the company's stock, indicating credibility among professional investors. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Individual investors hold about 12% of the stock, while insiders own approximately 0.14%.